Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS
· Delayed Price · Currency is USD
22.46
-0.44 (-1.92%)
Jun 27, 2025, 3:52 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
$672,658
Profits / Employee
$105,470
Market Cap
44.59B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
American Oncology Network | 1,914 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Daiichi Sankyo Company News
- 4 days ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 5 days ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 11 days ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 19 days ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 26 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 26 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 27 days ago - DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer - Benzinga
- 4 weeks ago - ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial - Benzinga